Optimi Health Corp. - Chief Science Officer, Justin Kirkland
Chief Science Officer, Justin Kirkland
Source: Optimi Health
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Optimi Health Corp (OPTI) has completed a planned expansion of the on-site analytical laboratory at its Princeton, British Columbia facility
  • The on-site lab is purpose-built inside one of Optimi’s EU-GMP capable 10,000 square foot, indoor growing facilities
  • Optimi Chief Science Officer, Justin Kirkland, will oversee the company’s analytical operations
  • Optimi Health produces and supplies natural, EU-GMP grade psilocybin and functional mushrooms that focus on the health and wellness markets
  • Shares of Optimi Health Corp are up 1.85 per cent, trading at $0.275 at 09:41 AM ET

Optimi Health (OPTI) has expanded the analytical laboratory at its Princeton, British Columbia facility.

The on-site lab is purpose-built inside one of Optimi’s EU-GMP capable 10,000 square foot, indoor growing facilities dedicated to the cultivation of safe, high-quality psychedelic and functional mushrooms.

Optimi Chief Science Officer, Justin Kirkland, will oversee the company’s analytical operations.

“Our analytical lab will prove a completely consistent dosage on natural psilocybin products that will meet stringent FDA and EU-GMP standards,” said Kirkland.

“We will measure and ensure integrity, ongoing stability, and accuracy in all of our natural psilocybin and psychedelic formulations and are finalizing our standard perating Procedures to meet Health Canada and international standards.” he added.

The newly enlarged analytical laboratory will operate as a division of Optimi Labs Inc., a wholly-owned subsidiary of Optimi Health. It is designed both for research into the company’s proprietary formulations and extraction methods and to be utilized by clients and partners and approved companies to conduct investigations into molecular discovery with restricted psychedelic compounds.

Optimi CEO Bill Ciprick noted that the lab expansion is a critical component of the company’s planned revenue strategy.

“While Optimi’s main focus remains the cultivation of a safe, scalable supply of natural EU-GMP psilocybin, we realize that operationalizing a future for psychedelic science in which the largest number of authorized patients have access to these medicines requires a more robust research infrastructure than currently exists, particularly in light of the current levels of interest and demand from so many entities across the space,” Ciprick added.

Alongside its primary objective of becoming a tier-one ingredient supplier of naturally cultivated psilocybin mushrooms and extracts, the company intends to develop efforts on third parties requiring supplementary facilities and analytical support in drug discovery processes as well as for single and multi-site clinical trials.

Optimi Health is a homegrown, Canadian success story producing and supplying natural, EU-GMP grade psilocybin and functional mushrooms that focus on the health and wellness markets.

Shares of Optimi Health Corp are up 1.85 per cent, trading at $0.275 at 09:41 AM ET.

More From The Market Herald

" Red Light Holland (CSE:TRIP) utilizing 3D movement data for psychedelic therapy

Red Light Holland (TRIP) subsidiary Radix Motion has received an International Preliminary Report on Patentability on the patent application filed in 2020. ...

" Algernon (CSE:AGN) receives FDA Orphan Drug Designation for Ifenprodil to treat Idiopathic Pulmonary Fibrosis

Algernon Pharmaceuticals (AGN) has been granted Orphan Drug Designation (ODD) for Ifenprodil to treat Idiopathic Pulmonary Fibrosis (IPF).

" Lobe Sciences (CSE:LOBE) advances clinical development plans for its proprietary psilocin product

Lobe Sciences (LOBE) released an update for its clinical development plans for its proprietary Psilocin-based compound L-130.